Precision treatment in colorectal cancer: Now and the future

Medicine and Dentistry

• Colorectal Carcinoma 100%
• Pharmacogenetics 100%
• Proto Oncogene 66%
• Exon 66%
• In Vitro 33%
• Next Generation Sequencing 33%
• Therapeutic Agent 33%
• Biological Marker 33%
• Anticarcinogen 33%
• Tumor Cell 33%
• Primary Tumor 33%
• Drug Screening 33%
• Irinotecan 33%
• Treatment Response 33%
• Epidermal Growth Factor Receptor 33%
• Positron Emission Tomography 33%
• Metastatic Colorectal Cancer 33%
• Fluorine-18 33%
• Circulating Tumor DNA 33%
• Immunohistochemistry 33%
• Cetuximab 33%
• Panitumumab 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Colorectal Carcinoma 100%
• Fluorine 18 50%
• Metastatic Colorectal Cancer 50%
• Biological Marker 50%
• Anticarcinogen 50%
• Primary Tumor 50%
• Panitumumab 50%
• Irinotecan 50%
• Circulating Tumor DNA 50%
• Cetuximab 50%
• Epidermal Growth Factor Receptor 50%
• Pentaerythrityl Tetranitrate 50%

Biochemistry, Genetics and Molecular Biology

• KRAS 100%
• Pharmacogenetics 100%
• Exon 66%
• Proto Oncogene 66%
• Next Generation Sequencing 33%
• Anticancer 33%
• Epidermal Growth Factor Receptor 33%
• Positron Emission Tomography 33%
• Circulating Tumor DNA 33%
• Cetuximab 33%
• Targeted Therapy 33%
• Drug Screening 33%
• Panitumumab 33%